Zimmer Biomet Holdings, Inc. $ZBH Shares Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. trimmed its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 10.4% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 398,121 shares of the medical equipment provider’s stock after selling 46,412 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.21% of Zimmer Biomet worth $35,365,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the company. OMERS ADMINISTRATION Corp purchased a new position in shares of Zimmer Biomet in the second quarter worth about $922,000. Hsbc Holdings PLC purchased a new stake in Zimmer Biomet during the 2nd quarter valued at about $35,417,000. Nykredit A S acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $3,419,000. Legal & General Group Plc acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $126,167,000. Finally, Rakuten Investment Management Inc. acquired a new stake in Zimmer Biomet in the 2nd quarter valued at about $2,945,000. 88.89% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Zimmer Biomet

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Zimmer Biomet’s third-quarter sales of $2.063 billion and adjusted EPS of $1.90 topped analyst estimates. The company also raised its full-year 2026 outlook; hip and S.E.T. sales helped offset softer knee results. Third-quarter results
• Positive Sentiment: Analysts raised targets, with UBS moving to $130 and keeping a Buy rating, and RBC increasing its target to $125 with an Outperform rating. These revisions signal improved expectations for the shares. UBS analyst rating
• Neutral Sentiment: JPMorgan, Citi, and Wells Fargo also lifted their price targets, but retained Neutral or Equal Weight ratings. Bernstein raised its target to $107 while maintaining Market Perform, reflecting a more cautious view.
• Negative Sentiment: Knee-market challenges and margin pressure temper the results. Reported diluted EPS fell 13.8% year over year to $1.00, although adjusted EPS was flat at $1.90, so investors may weigh the outlook improvement against operating pressures. Quarterly outlook and knee-market challenges

Analyst Ratings Changes

Several brokerages have recently weighed in on ZBH. Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Barclays upgraded Zimmer Biomet to a “hold” rating in a research report on Wednesday, October 7th. Argus reiterated a “buy” rating and set a $125.00 price target on shares of Zimmer Biomet in a research report on Thursday, October 22nd. JPMorgan Chase & Co. lifted their price objective on Zimmer Biomet from $117.00 to $120.00 and gave the company a “neutral” rating in a research note on Thursday. Finally, BMO Capital Markets reaffirmed a “market perform” rating on shares of Zimmer Biomet in a research note on Monday, September 28th. Seven analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $111.95.

Zimmer Biomet Stock Performance

Shares of Zimmer Biomet stock opened at $107.08 on Friday. The firm has a market capitalization of $20.42 billion, a P/E ratio of 27.11, a P/E/G ratio of 2.65 and a beta of 0.50. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $112.54. The company has a quick ratio of 0.94, a current ratio of 1.46 and a debt-to-equity ratio of 0.49. The firm’s 50 day moving average is $95.01 and its two-hundred day moving average is $91.99.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. Zimmer Biomet had a net margin of 8.95% and a return on equity of 13.02%. The firm’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a $0.24 dividend. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. Zimmer Biomet’s payout ratio is 23.36%.

Insiders Place Their Bets

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of the firm’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the transaction, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.